Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)
21.79
-1.06 (-4.64%)
Mar 20, 2026, 3:04 PM CST
SHE:002393 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | - | 1,639 | 1,989 | 1,793 | 1,652 |
Short-Term Investments | - | 80.46 | 70.72 | - | - |
Trading Asset Securities | - | 573.36 | 160.54 | 200.32 | - |
Cash & Short-Term Investments | 2,039 | 2,293 | 2,220 | 1,994 | 1,652 |
Cash Growth | -11.09% | 3.27% | 11.37% | 20.69% | 5.80% |
Accounts Receivable | - | 427.03 | 312.51 | 387.99 | 414 |
Other Receivables | - | 3.21 | 4.4 | 10.87 | 7.43 |
Receivables | - | 430.24 | 316.91 | 398.86 | 421.43 |
Inventory | - | 224.37 | 176.28 | 199.15 | 228.78 |
Other Current Assets | - | 112.29 | 105.11 | 33.78 | 54.32 |
Total Current Assets | - | 3,060 | 2,819 | 2,625 | 2,356 |
Property, Plant & Equipment | - | 1,020 | 976.48 | 1,030 | 1,137 |
Long-Term Investments | - | 92.77 | 194.05 | 1,431 | 1,500 |
Goodwill | - | 70.72 | - | - | - |
Other Intangible Assets | - | 184.06 | 124.86 | 135.49 | 144.22 |
Long-Term Deferred Tax Assets | - | 43.8 | 39.47 | 33.71 | 16.31 |
Long-Term Deferred Charges | - | 0.92 | - | - | - |
Other Long-Term Assets | - | 1,313 | 1,627 | 35.98 | 37.49 |
Total Assets | - | 5,786 | 5,781 | 5,291 | 5,191 |
Accounts Payable | - | 135.84 | 90.36 | 146.38 | 90.49 |
Accrued Expenses | - | 290.83 | 251.39 | 297.23 | 228.97 |
Short-Term Debt | - | 39.79 | 28.6 | 39.29 | 28.14 |
Current Portion of Leases | - | 2.84 | 0.87 | 0.42 | 0.4 |
Current Income Taxes Payable | - | 11.72 | 14.6 | 12.22 | 5.79 |
Current Unearned Revenue | - | 34 | 14.94 | 30.54 | 11.29 |
Other Current Liabilities | - | 231.5 | 225.5 | 203.9 | 187.4 |
Total Current Liabilities | - | 746.53 | 626.27 | 729.98 | 552.47 |
Long-Term Leases | - | 8.38 | 3.95 | 5.37 | 6.2 |
Long-Term Unearned Revenue | - | 28.51 | 27.93 | 31.83 | 31.68 |
Pension & Post-Retirement Benefits | - | 11 | 11.35 | 11.28 | 11.31 |
Long-Term Deferred Tax Liabilities | - | 181.01 | 204.09 | 162.04 | 178.77 |
Other Long-Term Liabilities | - | 10.11 | 3.58 | 1.16 | - |
Total Liabilities | - | 985.54 | 877.17 | 941.66 | 780.42 |
Common Stock | - | 257.9 | 184.28 | 183.99 | 182.45 |
Additional Paid-In Capital | - | 1,652 | 1,721 | 1,712 | 1,692 |
Retained Earnings | - | 1,942 | 1,857 | 1,551 | 1,512 |
Treasury Stock | - | -61.05 | -24.09 | -21.01 | - |
Comprehensive Income & Other | - | 978.46 | 1,165 | 924.04 | 1,025 |
Total Common Equity | 4,970 | 4,770 | 4,903 | 4,349 | 4,411 |
Minority Interest | - | 30.06 | - | - | - |
Shareholders' Equity | 5,003 | 4,800 | 4,903 | 4,349 | 4,411 |
Total Liabilities & Equity | - | 5,786 | 5,781 | 5,291 | 5,191 |
Total Debt | 33.98 | 51.01 | 33.42 | 45.08 | 34.74 |
Net Cash (Debt) | 2,005 | 2,242 | 2,187 | 1,949 | 1,617 |
Net Cash Growth | -10.58% | 2.51% | 12.23% | 20.49% | 4.86% |
Net Cash Per Share | 7.76 | 8.75 | 8.46 | 7.58 | 6.34 |
Filing Date Shares Outstanding | 260.63 | 256.27 | 260.86 | 257.59 | 255.44 |
Total Common Shares Outstanding | 256.18 | 256.27 | 260.86 | 257.59 | 255.44 |
Working Capital | - | 2,313 | 2,192 | 1,895 | 1,804 |
Book Value Per Share | 19.40 | 18.61 | 18.80 | 16.88 | 17.27 |
Tangible Book Value | 4,721 | 4,515 | 4,779 | 4,214 | 4,266 |
Tangible Book Value Per Share | 18.43 | 17.62 | 18.32 | 16.36 | 16.70 |
Buildings | - | 989.32 | 930.62 | 950.07 | 941.9 |
Machinery | - | 552.53 | 507.9 | 517.78 | 496.86 |
Construction In Progress | - | 17.61 | 7.04 | 12.79 | 154.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.